Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone

Cora Sternberg

REFERENCE: Abstract 4010, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007CORA STERNBERG, San Camillo and Forlanini Hospital, RomeSatraplatin could provide a new option for patients with hormone refractory prostate cancer, by giving improved progression-free survival and time to pain progression. Anna Lacey spoke toCora Sternbergabout her group’s results from an international phase III trial, which were announced in Barcelona.

Peter Ravdin

Significant Drop in US Breast Cancer Incidence Linked to Reduction in Hormone Replacement Therapy

REFERENCE: 2007 Chemotherapy Foundation SymposiumPETER RAVDIN, MD Anderson Cancer Center, HoustonA large registry-based study has provided strong evidence that a significant drop in breast cancer incidence in 2003 was due to the decreased use of hormone replacement therapy. Derek Thorne heard more about the study and its implications when he interviewedPeter Ravdinin New York.

David Vesole

Low-Dose Dexamethasone Better For Newly Diagnosed Multiple Myeloma Treated With Lenalidomide

REFERENCE: 2007 Chemotherapy Foundation SymposiumDAVID VESOLE, St Vincent’s Comprehensive Cancer Center, New YorkIn newly diagnosed multiple myeloma, lenalidomide plus a lower dose of dexamethasone appears to be favorable for patients, and with a one-year survival rate of 96%, it could be the best result seen in this setting. During the New York symposium Derek Thorne put questions toDavid Vesoleabout his findings and their clinical implications.

Daniel DeAngelo

Young Adults With Acute Lymphoblastic Leukemia: Better Success With Pediatric Regimens

REFERENCE: 2007 Chemotherapy Foundation SymposiumDANIEL DEANGELO, Dana-Farber Cancer Institute, BostonYoung adults with ALL may be treated more effectively by using chemotherapy regimens traditionally reserved for children, rather than by using therapies recommended for adults. This came out of a talk in New York given byDaniel DeAngelo, and he later discussed with Peter Goodwin his views and preliminary results from an ongoing trial, including dose-intense asparagine depletion therapy.

LISTEN

To subscribe to the ASCO Audio Journal of Oncology podcast please go toASCO Audio Journal of Oncology in Advance Presentationsorclick here.